Colon cancer Cancer Colon
Conditions
Interventions
1. Arm 1: Panorex (900 mg) (1 x 500 mg 5-FU, 4 x 100 mg Luecovorin)
2. Arm 2: 5-FU - 425 mg/m2/d x 5 days for six courses
Leucovorin - 20 mg.m2/day x 5 days for six courses
3. Arm 3: Panorex alone (900 mg)
Sponsors
Glaxo Wellcome (UK)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Histopathologically documented stage III (Dukes C) colon cancer 2. Less than 6 weeks since surgical removal of the tumour 3. Tumour-free margin of resection 4. Total resection of tumour by laparoscopy is an exclusion 5. Age >18: World Health Organisation (WHO) performance status of 0, 1 or 2: Life expectancy at least 12 months 6. Adequate haematological, hepatic and renal function 7. No metastatic, recurrent, locally advanced cancer or previous history of cancer
Exclusion criteria
Exclusion criteria: Not provided at time of registration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed